Row
T
TGTXAI Stock Diagnostic Report
TG Therapeutics GAAP EPS of $0.05 misses by $0.26, revenue of $240.34M beats by $10.55M
TG Therapeutics' earnings per share (EPS) for the second quarter of 2026 fell short of expectations, while revenue exceeded expectations, resulting in a mixed performance.
View Source Article ↗AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time